Screener
Icahn Enterprises IEP Pharma — Partners Capital
Other segment segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Icahn Enterprises in its filing.
Tagged under the XBRL concept us-gaap:PartnersCapital.
The source filing: Icahn Enterprises’s 10-Q, filed August 5, 2026.
- Filed
- Aug 4, 2026, 8:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001104659-26-090605
| Line item | Investment | Energy | Automotive | Food Packaging | Real Estate | Home Fashion | Pharma | Holding Company | Consolidated |
|---|---|---|---|---|---|---|---|---|---|
| Accounts payable, accrued expenses and other liabilities | $752 | $1,578 | $711 | $110 | $28 | $38 | $63 | $75 | $3,355 |
| Securities sold, not yet purchased, at fair value | 1,000 | — | — | — | — | — | — | — | 1,000 |
| Debt | — | 1,783 | 25 | 129 | 1 | 25 | — | 4,426 | 6,389 |
| Total liabilities | 1,752 | 3,361 | 736 | 239 | 29 | 63 | 63 | 4,501 | 10,744 |
| Equity attributable to Icahn Enterprises | 1,978 | 575 | 554 | 178 | 1,128 | 148 | 153 | (3,705) | 1,009 |
| Equity attributable to non-controlling interests | 593 | 533 | — | 11 | — | — | — | — | 1,137 |
| Total equity | 2,571 | 1,108 | 554 | 189 | 1,128 | 148 | 153 | (3,705) | 2,146 |
| Total liabilities and equity | $4,323 | $4,469 | $1,290 | $428 | $1,157 | $211 | $216 | $796 | $12,890 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Icahn Enterprises's pharma — partners capital?
- Icahn Enterprises (IEP) reported pharma — partners capital of $153M in Q2 2026.
- How has Icahn Enterprises's pharma — partners capital changed year-over-year?
- Icahn Enterprises's pharma — partners capital decreased by 22.3% year-over-year, from $197M to $153M.
- What is the long-term trend for Icahn Enterprises's pharma — partners capital?
- Over 4 years (2021 to 2025), Icahn Enterprises's pharma — partners capital has grown at a -7.8% compound annual growth rate (CAGR), from $1.06B to $764M.
- What does pharma — partners capital mean?
- Represents the equity interest held by partners or parent entities within the pharmaceutical segment. This metric indicates the net investment value attributable to the primary stakeholders after accounting for all liabilities. It is essential for understanding the ownership structure and equity base of the business unit.
Ask your AI about Icahn Enterprises's pharma — partners capital.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude